Top

Published in:

01-06-2020 | Fibromyalgia | Review

Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases

Author: Ilke Coskun Benlidayi

Published in: Rheumatology International | Issue 6/2020

Abstract

Fibromyalgia is one of the numerous comorbidities that may accompany inflammatory rheumatic diseases. Concomitant fibromyalgia in inflammatory rheumatic conditions can interfere with symptomatology, disease activity and overall management plan. The aim of the present narrative review article was to discuss the current evidence on (i) the prevalence/frequency of comorbid fibromyalgia in inflammatory rheumatic conditions, (ii) the role of fibromyalgia on disease activity, (iii) the impact of concomitant fibromyalgia on biological disease-modifying antirheumatic treatment outcomes and (iv) potential effectiveness of biological disease-modifying antirheumatic drugs on fibromyalgia-related symptoms among patients with inflammatory rheumatic diseases. A literature search was conducted through PubMed/MEDLINE Cochrane and Web of Science databases by using relevant keywords and their combinations. Studies representing different geographical areas of the world revealed that frequency rates of fibromyalgia are higher in inflammatory rheumatic diseases than those in the general population. Comorbid fibromyalgia interferes not only with the disease activity scores but also with the treatment outcomes and management plan. Further evidence is warranted in order to determine the potential benefits of biological disease-modifying antirheumatic drugs on fibromyalgia-related symptoms in patients with inflammatory rheumatic diseases.

Muilu P, Rantalaiho V, Kautiainen H, Virta LJ, Eriksson JG, Puolakka K (2019) Increasing incidence and shifting profile of idiopathic inflammatory rheumatic diseases in adults during this millennium. Clin Rheumatol 38:555–562. https://doi.org/10.1007/s10067-018-4310-0 CrossRefPubMed

Coskun Benlidayi I, Gokcen N, Sariyildiz A, Sarpel T (2019) They have got the blues: patient's mood- and disease activity-related psychological burden of rheumatoid arthritis on caregivers. Int J Psychiatry Clin Pract 23:84–89. https://doi.org/10.1080/13651501.2018.1492728 CrossRefPubMed

Cook MJ, Bellou E, Bowes J, Sergeant JC, O’Neill TW, Barton A, Verstappen SMM (2018) The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank. Rheumatology (Oxford) 57:2172–2182. https://doi.org/10.1093/rheumatology/key224 CrossRef

Coskun Benlidayi I (2018) Sleep impairment: an obstacle to achieve optimal quality of life in rheumatoid arthritis. Rheumatol Int 38:2183–2192. https://doi.org/10.1007/s00296-018-4155-5 CrossRefPubMed

Ursum J, Nielen MM, Twisk JW, Peters MJ, Schellevis FG, Nurmohamed MT, Korevaar JC (2013) Increased risk for chronic comorbid disorders in patients with inflammatory arthritis: a population based study. BMC Family Pract 14:199CrossRef

Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC (2016) Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 356:664–672. https://doi.org/10.1124/jpet.115.230060 CrossRefPubMedPubMedCentral

Bäckryd E, Tanum L, Lind AL, Larsson A, Gordh T (2017) Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J Pain Res 10:515–525. https://doi.org/10.2147/JPR.S128508 CrossRefPubMedPubMedCentral

Moltó A, Etcheto A, Gossec L, Boudersa N, Claudepierre P, Roux N, Lemeunier L, Martin A, Sparsa L, Coquerelle P, Soubrier M, Perrot S, Dougados M (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77:533–540. https://doi.org/10.1136/annrheumdis-2017-212378 CrossRefPubMed

Bello N, Etcheto A, Béal C, Dougados M, Moltó A (2016) Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis. Arthritis Res Ther 18:42. https://doi.org/10.1186/s13075-016-0943-z CrossRefPubMedPubMedCentral

10.

Chakr RMDS, Brenol C, Ranzolin A, Bernardes A, Dalosto AP, Ferrari G, Scalco S, Olszewski V, Kohem C, Monticielo O, Brenol JCT, Xavier RM (2017) Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia. Rev Bras Reumatol Engl Ed 57:403–411. https://doi.org/10.1016/j.rbre.2017.01.004 CrossRefPubMed

11.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3 CrossRefPubMed

12.

Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M (2010) Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 39:448–453. https://doi.org/10.1016/j.semarthrit.2008.12.003 CrossRefPubMed

13.

Jones GT, Atzeni F, Beasley M, Flüß E, Sarzi-Puttini P, Macfarlane GJ (2015) The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol 67:568–575. https://doi.org/10.1002/art.38905 CrossRefPubMed

14.

Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129–132. https://doi.org/10.1016/j.semarthrit.2017.01.005 CrossRefPubMed

15.

Macfarlane GJ, Pathan E, Siebert S, Packham J, Gaffney K, Choy E, Sengupta R, Atzeni F, Martin KR, Jones GT, Dean LE (2019) AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatol 3:19. https://doi.org/10.1186/s41927-019-0066-7 CrossRefPubMedPubMedCentral

16.

Macfarlane GJ, MacDonald RIR, Pathan E, Siebert S, Gaffney K, Choy E, Packham J, Martin KR, Haywood K, Sengupta R, Atzeni F, Jones GT (2018) Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology (Oxford) 57:1982–1990. https://doi.org/10.1093/rheumatology/key206 CrossRef

17.

Macfarlane GJ, Barnish MS, Pathan E, Martin KR, Haywood KL, Siebert S, Packham J, Atzeni F, Jones GT (2017) Co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: results from a UK National Register. Arthritis Rheumatol 69:2144–2150. https://doi.org/10.1002/art.40185 CrossRefPubMed

18.

Lage-Hansen PR, Chrysidis S, Lage-Hansen M, Hougaard A, Ejstrup L, Amris K (2016) Concomitant fibromyalgia in rheumatoid arthritis is associated with the more frequent use of biological therapy: a cross-sectional study. Scand J Rheumatol 45:45–48. https://doi.org/10.3109/03009742.2015.1046484 CrossRefPubMed

19.

Gheita TA, Sayed S, Gheita HA, Kenawy SA (2016) Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome. Int J Rheum Dis 19:294–299. https://doi.org/10.1111/1756-185X.12426 CrossRefPubMed

20.

Moon SJ, Kang KY, Kwok SK, Ju JH, Hong YS, Park SH, Jeon CH, Choi ST, Song JS, Min JK (2018) Differences in quality of life determinants according to the presence of fibromyalgia in middle-aged female patients with systemic lupus erythematosus: a multicenter, cross-sectional, single-ethnicity cohort. Int J Rheum Dis 21:1173–1184. https://doi.org/10.1111/1756-185X.13320 CrossRefPubMed

21.

Choi BY, Oh HJ, Lee YJ, Song YW (2016) Prevalence and clinical impact of fibromyalgia in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 34(2 Suppl 96):S9–13PubMed

22.

Perrot S, Peixoto M, Dieudé P, Hachulla E, Avouac J, Ottaviani S, Allanore Y (2017) Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. Clin Exp Rheumatol 35(Suppl 105):35–42PubMed

23.

Torrente-Segarra V, Corominas H, Sánchez-Piedra C, Fernández-Castro M, Andreu JL, Martínez-Taboada VM, Olivé A, Rosas J, Sánchez-Alonso F, SJOGRENSER Study Group of the Spanish Society of Rheumatology (2017) Fibromyalgia prevalence and associated factors in primary Sjögren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER). Clin Exp Rheumatol 35(Suppl 105):28–34PubMed

24.

Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Pérez-Vicente S, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Ibañez-Ruán J, Horcada L, Sánchez-Atrio A, Montilla C, Rodríguez-Gómez M, Díez-Álvarez E, Martinez-Taboada V, Andreu JL, Fernández-Berrizbeitia O, Hernández-Beriain JA, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Marras C, Bonilla G, Pego-Reigosa JM, RELESSER Study Group of the Spanish Society of Rheumatology (SER); Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER) (2016) Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus. Clin Exp Rheumatol 34(2 Suppl 96):S40–S47PubMed

25.

Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A (2014) Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int 34:1275–1280. https://doi.org/10.1007/s00296-014-2972-8 CrossRefPubMed

26.

Toprak M, Erden M, Alpaycı M, Ediz L, Yazmalar L, Hız Ö, Tekeoğlu İ (2017) The frequency and effect of fibromyalgia in patients with Behçet's disease. Turk J Phys Med Rehabil 63:160–164. https://doi.org/10.5606/tftrd.2017.291 CrossRefPubMedPubMedCentral

27.

El-Rabbat MS, Mahmoud NK, Gheita TA (2018) Clinical significance of fibromyalgia syndrome in different rheumatic diseases: Relation to disease activity and quality of life. Reumatol Clin 14:285–289. https://doi.org/10.1016/j.reuma.2017.02.008 CrossRef

28.

Graceffa D, Maiani E, Sperduti I, Ceralli F, Bonifati C (2015) Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis. Clin Exp Dermatol 40:136–141. https://doi.org/10.1111/ced.12504 CrossRefPubMed

29.

Wach J, Letroublon MC, Coury F, Tebib JG (2016) Fibromyalgia in spondyloarthritis: effect on disease activity assessment in clinical practice. J Rheumatol 43:2056–2063CrossRef

30.

Santos-Faria D, Dougados M, Gossec L, Perrot S, Moltó A (2019) Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis. Rheumatol Int 39:141–146. https://doi.org/10.1007/s00296-018-4200-4 CrossRefPubMed

31.

Shah K, Paris M, Mellars L, Changolkar A, Mease PJ (2017) Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open 28(3):e000588. https://doi.org/10.1136/rmdopen-2017-000588 CrossRef

32.

Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749–1754. https://doi.org/10.3899/jrheum.151491 CrossRefPubMed

33.

Joharatnam N, McWilliams DF, Wilson D, Wheeler M, Pande I, Walsh DA (2015) A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis. Arthritis Res Ther 17:11. https://doi.org/10.1186/s13075-015-0525-5 CrossRefPubMedPubMedCentral

34.

Wolfe F, Walitt B, Perrot S, Rasker JJ, Häuser W (2018) Fibromyalgia diagnosis and biased assessment: sex, prevalence and bias. PLoS ONE 13:e0203755. https://doi.org/10.1371/journal.pone.0203755 CrossRefPubMedPubMedCentral

35.

Salaffi F, Di Carlo M, Carotti M, Sarzi-Puttini P (2018) The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. Rheumatol Int 38:1911–1918. https://doi.org/10.1007/s00296-018-4096-z CrossRefPubMed

36.

Salaffi F, Gerardi MC, Atzeni F, Batticciotto A, Talotta R, Draghessi A, Di Carlo M, Sarzi-Puttini P (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37:2035–2042. https://doi.org/10.1007/s00296-017-3792-4 CrossRefPubMed

37.

Gist AC, Guymer EK, Eades LE, Leech M, Littlejohn GO (2018) Fibromyalgia remains a significant burden in rheumatoid arthritis patients in Australia. Int J Rheum Dis 21:639–646. https://doi.org/10.1111/1756-185X.13055 CrossRefPubMed

38.

Ahmad J, Blumen H, Tagoe CE (2015) Association of antithyroid peroxidase antibody with fibromyalgia in rheumatoid arthritis. Rheumatol Int 35:1415–1421. https://doi.org/10.1007/s00296-015-3278-1 CrossRefPubMed

39.

Kilicarslan A, Yurdakul FG, Bodur H (2018) Diagnosing fibromyalgia in rheumatoid arthritis: the importance of assessing disease activity. Turk J Phys Med Rehabil 64:133–139. https://doi.org/10.5606/tftrd.2018.1618 CrossRefPubMedPubMedCentral

40.

Kim H, Cui J, Frits M, Iannaccone C, Coblyn J, Shadick NA, Weinblatt ME, Lee YC (2017) Fibromyalgia and the prediction of two-year changes in functional status in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 69:1871–1877. https://doi.org/10.1002/acr.23216 CrossRef

41.

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172CrossRef

42.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62:600–610CrossRef

43.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 38:1113–1122CrossRef

44.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B (2016) 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 46:319–329. https://doi.org/10.1016/j.semarthrit.2016.08.012 CrossRefPubMed

45.

Larrosa Pardo F, Bondesson E, Schelin MEC, Jöud A (2019) A diagnosis of rheumatoid arthritis, endometriosis or IBD is associated with later onset of fibromyalgia and chronic widespread pain. Eur J Pain 23:1563–1573. https://doi.org/10.1002/ejp.1432 CrossRefPubMed

46.

Macchioni P, Salvarani C, Possemato N, Gutierrez M, Grassi W, Gasparini S, Perricone C, Perrotta FM, Grembiale RD, Bruno C, Tripolino C, Govoni M, Ciancio G, Farina I, Ramonda R, Frallonardo P, Desiati F, Scarpa R, Costa L, Zabotti A, De Vita S, D'Attino RM, Gualberti G, Merolla R, di Luzio PU, Aldigeri R, Marchesoni A (2019) Ultrasonographic and clinical assessment of peripheral enthesitis in patients with psoriatic arthritis, psoriasis, and fibromyalgia syndrome: the ULISSE study. J Rheumatol 46:904–911. https://doi.org/10.3899/jrheum.171411 CrossRefPubMed

47.

Curtis JR, Herrem C, Ndlovu MN, O'Brien C, Yazici Y (2017) A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. Arthritis Res Ther 19:215. https://doi.org/10.1186/s13075-017-1412-z CrossRefPubMedPubMedCentral

48.

Inanc N, Yilmaz-Oner S, Can M, Sokka T, Direskeneli H (2014) The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis. J Rheumatol 41:1755–1760. https://doi.org/10.3899/jrheum.131171 CrossRefPubMed

49.

Provan SA, Austad C, Halsaa V, Hammer HB, Kvien TK, Uhlig T (2019) Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register. Clin Exp Rheumatol 37(Suppl 116):58–62PubMed

50.

Coskun Benlidayi I (2018) Fibromyalgia as a challenge for patients and physicians. Rheumatol Int 38:2345. https://doi.org/10.1007/s00296-018-4138-6 CrossRefPubMed

51.

Basu N, Kaplan CM, Ichesco E, Larkin T, Harris RE, Murray A, Waiter G, Clauw DJ (2018) Neurobiologic features of fibromyalgia are also present among rheumatoid arthritis patients. Arthritis Rheumatol 70:1000–1007CrossRef

52.

Ragab O, Khairy N, Taha R, Iskander M (2017) Serum seratonin in rheumatoid arthritis patients: relation to rheumatoid factor positivity, clinical manifestations and fibromyalgia. Egypt Rheumatol 40:149–153. https://doi.org/10.1016/j.ejr.2017.09.002 CrossRef

53.

Berthelot JM, Bart G, Darrieutort-Lafitte C, Le Goff B, Guillot P, Glémarec J, Maugars Y (2019) Pain catastrophising worsens RAPID3 in all rheumatologic conditions. Clin Exp Rheumatol 37:600–607PubMed

54.

Bal A, Sayiner Çaglar N, Çaglar Okur S, Akin T, Aytekin E, Cetin E, Pekin Dogan Y, Erdem IH, Aysar O (2015) The effect of fibromyalgia on disease activity in patients with rheumatoid arthritis. İstanbul Med J 16:18–22. https://doi.org/10.5152/imj.2015.75436 CrossRef

55.

Garip Y, Güler T, Cifci N, Dortbas F, Karci AA (2016) Impact of fibromyalgia syndrome on quality of life in patients with Behçet’s disease. Turk J Phys Med Rehab 1:45–50. https://doi.org/10.5606/tftrd.2016.81226 CrossRef

56.

Piga M, Congia M, Gabba A, Figus F, Floris A, Mathieu A, Cauli A (2018) Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus. Lupus 27:190–198. https://doi.org/10.1177/0961203317716319 CrossRefPubMed

57.

Etchegaray-Morales I, Méndez-Martínez S, Jiménez-Hernández C, Mendoza-Pinto C, Alonso-García NE, Montiel-Jarquín A, López-Colombo A, García-Villaseñor A, Cardiel MH, García-Carrasco M (2017) Factors associated with health-related quality of life in mexican lupus patients using the lupusQol. PLoS ONE 12:e0170209. https://doi.org/10.1371/journal.pone.0170209 CrossRefPubMedPubMedCentral

58.

de Araújo AL, Paliares IC, de Araújo MI, Novo NF, Cadaval RA, Martinez JE (2015) The association of fibromyalgia and systemic lupus erythematosus change the presentation and severity of both diseases? Rev Bras Reumatol 55:37–42. https://doi.org/10.1016/j.rbr.2014.08.004 CrossRefPubMed

59.

Levy O, Segal R, Maslakov I, Markov A, Tishler M, Amit-Vazina M (2016) The impact of concomitant fibromyalgia on visual analogue scales of pain, fatigue and function in patients with various rheumatic disorders. Clin Exp Rheumatol 34(2 Suppl 96):120–124

60.

Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 38:878–882CrossRef

61.

Alunno A, Carubbi F, Stones S, Gerli R, Giacomelli R, Baraliakos X (2018) The impact of fibromyalgia in spondyloarthritis: from classification criteria to outcome measures. Front Med (Lausanne) 5:290. https://doi.org/10.3389/fmed.2018.00290 CrossRef

62.

Dougados M, Logeart I, Szumski A, Coindreau J, Jones H (2017) Evaluation of whether extremely high enthesitis or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores suggest fibromyalgia and confound the anti-TNF response in early non-radiographic axial spondyloarthritis. Clin Exp Rheumatol 35(Suppl 105):50–53PubMed

63.

Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'Dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64:640–647CrossRef

64.

Mian AN, Chaabo K, Wajed J, Subesinghe S, Gullick NJ, Kirkham B, Garrood T (2016) Rheumatoid arthritis patients with fibromyalgic clinical features have significantly less synovitis as defined by power Doppler ultrasound. BMC Musculoskelet Disord 17:404. https://doi.org/10.1186/s12891-016-1258-6 CrossRefPubMedPubMedCentral

65.

Segurado OG, Sasso EH (2014) Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 32(5 Suppl 85):S29–S34

66.

Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, Segurado OG, Sasso EH (2016) Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology (Oxford) 55:640–648. https://doi.org/10.1093/rheumatology/kev388 CrossRef

67.

Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL (2018) Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Semin Arthritis Rheum 47:472–477. https://doi.org/10.1016/j.semarthrit.2017.07.010 CrossRefPubMed

68.

da Silva Chakr RM, Brenol JC, Behar M, Mendonça JA, Kohem CL, Monticielo OA, Brenol CV, Xavier RM (2015) Is ultrasound a better target than clinical disease activity scores in rheumatoid arthritis with fibromyalgia? A case–control study. PLoS ONE 10:e0118620. https://doi.org/10.1371/journal.pone.0118620 CrossRefPubMedPubMedCentral

69.

Ghib LJ, Tămaş MM, Damian LO, Felea I, Muntean LM, Rednic N, Rednic S (2015) The role of ultrasonography in assessing disease activity in patients with rheumatoid arthritis and associated fibromyalgia. Med Ultrason 17:339–344. https://doi.org/10.11152/mu.2013.2066.173.ljg CrossRefPubMed

70.

Coskun Benlidayi I (2019) Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int 39:781–791. https://doi.org/10.1007/s00296-019-04251-6 CrossRefPubMed

71.

Imamura M, Targino RA, Hsing WT, Imamura S, Azevedo RS, Boas LS, Tozetto-Mendoza TR, Alfieri FM, Filippo TR, Battistella LR (2014) Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia. Clin Interv Aging 9:939–944. https://doi.org/10.2147/CIA.S60330 CrossRefPubMedPubMedCentral

72.

Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, Pérez-Tapia SM, Pérez-Sánchez G, Garcés-Alvarez ME, Aguirre-Cruz L, Velasco-Velázquez MA, Pavón L (2016) IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol 290:22–25. https://doi.org/10.1016/j.jneuroim.2015.11.011 CrossRefPubMed

73.

Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E (2012) Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 242:33–38. https://doi.org/10.1016/j.jneuroim.2011.10.013 CrossRefPubMed

74.

Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, Reis D (2013) Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol 31(6 Suppl 79):S60–63PubMed

75.

Rifbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML, Bliddal H, Kristensen LE, Danneskiold-Samsøe B, Amris K (2017) Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey. PLoS ONE 12:e0180014. https://doi.org/10.1371/journal.pone.0180014 CrossRefPubMedPubMedCentral

Title: Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases
Author: Ilke Coskun Benlidayi
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Fibromyalgia
Inflammatory Rheumatic Diseases
Fibromyalgia
Ankylosing Spondylitis
Spondyloarthropathy
Rheumatoid Arthritis
Published in: Rheumatology International / Issue 6/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-019-04506-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics

Prevalence of ankylosing spondylitis in a Chinese population: a systematic review and meta-analysis

Assessment of cervical spine involvement in rheumatoid arthritis patients in the era of biologics: a real-life, cross-sectional MRI study

Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis

Risk prediction of degenerative scoliosis combined with lumbar spinal stenosis in patients with rheumatoid arthritis: a case–control study

A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage